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Abstract
Coenzyme Q10 (CoQ10) deficiency is a clinically and genetically heterogeneous
subtype of mitochondrial disease. We report two girls with ataxia and mito-
chondrial respiratory chain deficiency who were shown to have primary
CoQ10 deficiency. Muscle histochemistry displayed signs of mitochondrial
dysfunction—ragged red fibers, mitochondrial paracrystalline inclusions, and
lipid deposits while biochemical analyses revealed complex II+III respiratory
chain deficiencies. MRI brain demonstrated cerebral and cerebellar atrophy.
Targeted molecular analysis identified a homozygous c.1015G>A, p.(Ala339Thr)
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COQ8A variant in subject 1, while subject 2 was found to harbor a single
heterozygous c.1029_1030delinsCA variant predicting a p.Gln343_Val344
delinsHisMet amino acid substitution. Subsequent investigations identified
a large-scale COQ8A deletion in trans to the c.1029_1030delinsCA allele. A
skin biopsy facilitated cDNA studies that confirmed exon skipping in the
fibroblast derived COQ8A mRNA transcript. This report expands the molec-
ular genetic spectrum associated with COQ8A-related mitochondrial disease
and highlights the importance of thorough investigation of candidate patho-
genic variants to establish phase. Rapid diagnosis is of the utmost impor-
tance as patients may benefit from therapeutic CoQ10 supplementation.
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1 | INTRODUCTION
Primary coenzyme Q10 (CoQ10, ubiquinone) deficiency
is a clinically and genetically heterogeneous subtype of
mitochondrial disease with a variable age of onset.1
CoQ10 is important for many processes including oxidative
phosphorylation, reactive oxygen species (ROS) scavenging
and pyrimidine synthesis.2 Cerebellar ataxia is the most
common clinical presentation associated with primary
CoQ10 deficiency, but other clinical features include car-
diomyopathy, encephalomyopathy, isolated myopathy and
nephrotic syndrome.1,3 While CoQ10 deficiency can occur
secondary to statin therapy4 or alternative gene defects,5
most cases are caused by biallelic pathogenic variants
affecting one of the nine enzymes involved in its biosynthe-
sis via the mevalonate pathway.6,7 Patients diagnosed with
primary CoQ10 deficiency often benefit from therapeutic
CoQ10 supplementation to ameliorate their symptoms.8,9
Rapid diagnosis is important to ensure therapeutic inter-
ventions are implemented where possible. We report the
biochemical, histochemical and molecular genetic findings
relating to two young, female patients, both of whom pres-
ented with early onset cerebellar ataxia and were found to
harbor recessive pathogenic variants in COQ8A.
2 | MATERIALS AND METHODS
2.1 | Case reports
Subject 1 is a 6-year-old Caucasian girl, born to non-
consanguineous parents, who presented at birth with
congenital hip dislocation. Hypotonia and developmental
delay were noted at 14 months of age. She had achieved
independent walking but was unstable by 3 years of
age, with frequent falls and difficulty climbing stairs.
No seizures were reported and familial pedigree analy-
sis was unremarkable except for seven cases of glau-
coma (Figure 1A); subject 1 has bilateral juvenile
glaucoma and underwent trabeculectomy in her left eye.
Her visual acuity is 20/60 (right eye) and 20/50 (left eye).
Physical examination at 6 years of age revealed short stat-
ure (<3rd centile) and dysmorphic features, namely
macrocephaly, dentinogenesis imperfecta, hypertelorism,
slight exophthalmos, bluish sclera, and learning disability
were reported. No ptosis or ophthalmoplegia were
observed. Absent lower extremities deep tendon reflexes,
hypotonia, and an abnormal wide-based gait were noted.
Electromyogram demonstrated myopathic motor unit
potentials while nerve conduction studies were normal.
Routine laboratory investigations revealed elevated serum
creatine kinase: 1143 UI/L (normal <225 UI/L) while
other investigations, including urinary organic acids and
blood lactate were unremarkable.
Skeletal radiographs were consistent with delayed
bone age, delayed posterior C1 and C2 fusion, and
coxofemoral dislocation. Brain magnetic resonance imag-
ing demonstrated decreased cerebral and cerebellar vol-
ume, supratentorial ventriculomegaly, and evidence of
an incidental arachnoid cyst (Figure 1B). Computed
tomography (CT) scan of the pelvis, thigh and legs dem-
onstrated no muscle fat replacement. At 6 years of age,
clinical suspicion of a mitochondrial disorder prompted
SYNOPSIS
COQ8A mutations cause pediatric ataxia with
CoQ10 deficiency; carrier testing is vital to confirm
recessive inheritance for accurate counseling.
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commencement of therapeutic CoQ10 (100 mg/day) and
deltoid biopsy for diagnostic investigations.
Subject 2 is a 16-year-old white British female, who at
24 months of age was noted to have expressive speech
difficulties and an unsteady gait with frequent falls. In
early childhood, she was assessed by a community pedi-
atric physician as having mild learning difficulties, a
developmental coordination disorder and exercise intol-
erance and referred to occupational therapy. She had an
intention tremor, difficulty tying shoe laces, poor toler-
ance of strenuous activity and although able to ride a
bike she could only do so for short distances before
fatiguing. She underwent cardiac assessment including
an echocardiogram at 4 years of age which was normal.
She was referred to neurology at 8 years of age. At that
time, she complained of being tired after only walking
short distances. She had an awkward gait and tended to
stumble and trip much more often than children her age
did; she was unable to skip or jump. Academically, sub-
ject 2 was 2-3 years behind her peers for both writing and
reading. On examination, she had a mild intention
tremor and dysdiadochokinesis. She had generalized mild
hypotonia. A brain MRI scan demonstrated pronounced
cerebellar atrophy (Figure 2) though she remained stable
for several years and was discharged back to community
follow-up at 13 years of age after a repeat MRI brain scan
showed no progression. At 15 years of age, she was re-
referred to neurology following the onset of generalized
tonic clonic seizures. The first episode was nocturnal and
lasted ~10 minutes preceded by a period of incoherence.
She had three further seizures over the following 3 months
and a sleep EEG supported a possible left temporal onset
and Levetiracetam was prescribed. She was found to be
hypertensive (blood pressure: 199/100 [exercise], 135/85
FIGURE 1 Pedigree, muscle histochemistry, neuroimaging, and molecular genetic findings for subject 1. A, Family pedigree for subject
1 reveals no evidence of consanguinity or additional affected individuals. Blue quadrant shading denotes the individuals reported to have
glaucoma. B, Sagittal T1 weighted (panel A), coronal T2-weighted (panel B) and axial T2-weighted (panels C and D) MR brain imaging shows
cerebellar atrophy, supratentorial ventriculomegaly, and a left temporal fossa arachnoid cyst (arrow head). C, Histochemical analysis of muscle
biopsy shows preserved general architecture using H&E stain at 100×magnification (A), focal necrotic fibers using H&E stain at 400×
magnification (B), pronounced lipid deposition on Oil-red-O staining at 200×magnification (C), ragged red fibers using Gomori modified
trichrome staining at 400×magnification (D), ragged blue fibers following the SDH reaction at 200×magnification (E), no COX-negative fibers
following the sequential COX-SDH reaction at 100×magnification (F). Transmission electron microscopy demonstrates marked mitochondrial
accumulation, varied mitochondrial size and shape with abnormal cristae (G: 3,000×magnification, H: 10,000×magnification) (G) and
paracrystalline (“parking lot”) mitochondrial inclusions (I, 40,000×magnification). D, Sequencing chromatograms portraying the homozygous
c.1015G>A, p.(Ala339Thr) COQ8A variant identified in subject 1 (S1) that is heterozygous in her mother (M) and father (F) and absent in
control DNA (C)
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[resting]) prompting treatment with antihypertensives and
enalapril. Progressive exercise intolerance led to cardiac
assessment at 15 years of age which revealed hypertension
and mild left ventricular dysfunction (fractional shortening
was 43%) with elevated lactate at 10.9 mmol/L (normal
range < 2.0 mmol/L) not explained by the degree of cardiac
dysfunction. She also started having generalized tonic-clonic
seizures and was commenced on anticonvulsant medica-
tion. Furthermetabolic investigations showed a persistently
elevated lactate (7.31 mmol/L, normal: <2.0 mmol/L), ele-
vated plasma alanine (790 μmol/L, normal range: 152–547
μmol/L), TCA metabolites in urine and normal CoQ10 in
white cell lysates. The possibility of a mitochondrial etiol-
ogy promptedmuscle biopsy for characterization.
2.2 | Histochemical and biochemical
analyses of respiratory chain enzymes
Histochemical analysis of serial muscle biopsy sections
was performed using standard protocols while biochemi-
cal analysis of respiratory chain enzyme activities in
mitochondrial enriched muscle biopsy homogenates was
performed as described previously.10 Assay of muscle
CoQ10 levels was undertaken for subject 2 using method-
ology reported elsewhere.11
2.3 | Molecular genetic analyses
Genetic analysis of the COQ8A gene (GenBank accession
NM_020247.4) was undertaken using oligonucleotides
targeting each coding exon (primer sequences supplied in
Table S1, Tab A). Sanger sequencing was undertaken using
the BigDye Terminator v3.1 kit (Life Technologies,
Carlsbad, CA) and an ABI3130xl automated sequencer per-
formed capillary electrophoresis according to the manufac-
turer's standard protocol (Life Technologies, Carlsbad, CA).
2.4 | RNA extraction and cDNA analysis
RNA extraction and first strand synthesis was performed as
reported previously12 using four overlapping primer pairs
designed using Primer3 (Table S1, Tab B) and specific to
the full length COQ8A transcript (GenBank accession
NM_020247.4). Aberrant amplicons were subject to
bandstab extraction, reamplification and resequencing.
FIGURE 2 Muscle histochemistry and neuroimaging for subject 2. Histochemical analysis of muscle biopsy demonstrates normal
architecture using H&E staining (panel A), fibers exhibiting signs of subsarcolemmal mitochondrial proliferation consistent with ragged red
fiber pathology on the SDH reaction (panel B) and Gomori modified trichrome staining (panel D). Sequential COX-SDH histochemistry
demonstrated all fibers have preserved COX activity with ragged-red pathology also evident (panel C); the scale bar on all images = 50 μm.
Sagittal T1-weighted MRI imaging shows marked cerebellar atrophy and widening of the fourth ventricle (panel E). T2-axial view (panel F)
shows normal cerebral cortices and no signal changes in basal ganglia. T2-sagittal view (panel G) and T2-axial view (panel H) show bilateral
hyperintensities in the dentate nuclei (arrows)
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Visual inspection of the sequencing chromatograms
was undertaken using FinchTV and BLAST was used to
align the sequence to the human genome (GRCh38).
2.5 | Long range PCR
Long range PCR was performed using the Promega
GoTaq Long kit and 100 ng whole genomic DNA from
Subject 2 and a healthy control to determine whether a
deep intronic splicing variant was present. Primers were
selected to amplify across the skipped exon 6 (exon 4F
and exon 7R, Table S1, Tab A). Following confirmation
of amplification using electrophoresis through a 1% aga-
rose gel, Sanger sequencing was performed as per the
manufacturers protocol to characterize the long-range
amplicon.
3 | RESULTS
3.1 | Histochemical and biochemical
assessment of muscle biopsy
Histochemical analyses of the muscle biopsies from both
subjects 1 and 2 report similar findings supportive of mito-
chondrial dysfunction. Both biopsies harbor a number of
ragged-red fibers (approximately 1% in subject 1 and 2%
for subject 2), consistent with mitochondrial proliferation.
Specifically, subject 1 muscle biopsy showed preserved
general architecture with isolated atrophic fibers and focal
necrosis (Figure 1C, Panels A and B), with small type
1 fibers and frequent lipid droplets (Figure 1C, Panel C).
There was evidence of subsarcolemmal mitochondrial
accumulation consistent with ragged-red fiber pathology
(Figure 1C, Panels D and E); no COX-deficient fibers were
observed (Figure 1C, Panel F). Muscle transmission elec-
tron microscopy demonstrated subsarcolemmal and
intermyofibrillary mitochondrial accumulation with vari-
ation in size and shape; paracrystalline inclusions, dense
granules, absent or abnormal cristae, lipid and glycogen
deposits, myofiber splitting and areas of severe myofiber
loss were also apparent (Figure 1C, Panels G-I). Subject
2 muscle biopsy revealed normal architecture (Figure 2,
Panel A) with approximately 2% of fibers demonstrating
mitochondrial proliferation (Figure 2, Panels B-D); again,
no COX-deficient fibers were observed (Figure 2, Panel C).
Biochemical analysis of respiratory chain complex activities
in muscle homogenates from subjects 1 and 2 also rev-
ealed striking similarities; both were found to have a
marked combined complex II+III deficiency, calculated
at 6% and 11% of mean control values, respectively.
Citrate synthase activity was found to be elevated,
consistent with mitochondrial proliferation. Determina-
tion of muscle CoQ10 levels was performed for subject
2 which confirmed a severe deficiency (5 pmol/mg,
normal range 140-580 pmol/mg).
3.2 | Molecular genetic investigations
Sequencing analysis revealed a homozygous c.1015G>A,
p.(Ala339Thr) COQ8A variant for subject 1; both parents
were subsequently found to be carriers, thereby con-
firming autosomal recessive inheritance. Given that the
c.1015G>A, p.(Ala339Thr) COQ8A variant is known to be
pathogenic,13 no additional investigations were required to
confirm the diagnosis. Sanger sequencing of subject 2's
blood-derived DNA sample demonstrated two heterozygous
COQ8A variants involving adjacent nucleotides, c.1029G>C
p.Gln343His and c.1030G>A p.Val344Met (Figure 3A).
Although initially suspected to be biallelic, carrier testing of
parental samples demonstrated that the variants occurred
in cis, with maternal inheritance of a single heterozygous
c.1029_1030delinsCA p.Gln343_Val344delinsHisMet variant
(Figure 3B). Given that the clinical diagnosis was consistent
with biallelic pathogenic COQ8A variants, additional experi-
ments were performed to determine whether a second vari-
ant was present but not detectable using the Sanger
sequencing strategy.
Initially, a fibroblast cell line was referred for cDNA
investigations that revealed abnormal splicing, with skip-
ping of exon 6 to create an in-frame c.731_853del mRNA
variant that is predicted to delete the p.Gly244_Gln284
residues from the protein (Figure 3C). Further interroga-
tion of the sequence showed only wild type sequence at
the c.1029_1030 locus (Figure 3D, denoted by an aster-
isk), thus establishing the aberrantly spliced allele to be
in trans with the c.1029_1030delinsCA variant. A long-
range PCR was performed to permit screening of the
intronic sequence for a putative splicing variant, however
agarose electrophoresis revealed a large-scale genomic
deletion (Figure 3E). Sanger resequencing characterized
the deletion break points as c.730+608 and c.854-25del
(GRCh38: g.226978131_226982653del) (Figure 3E), involving
exon 6 and much of the intronic sequence of introns 5 and
6 (Figure 3F). Subject 2's father was found to be heterozygous
for the c.730+608_854-25del p.Gly244_Gln284del variant
thereby confirming recessive inheritance of COQ8A variants
in this family.
4 | DISCUSSION
Ubiquinone, CoQ10, is a hydrophobic molecule com-
posed from a reactive quinone head group and a lipid tail
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comprising 10 carbon isoprenoid repeats.14 It is present
in all tissues, at varying levels and is vital for ATP pro-
duction in tissues with high energetic demands, shuttling
electrons from respiratory chain complexes I and II to
complex III during oxidative phosphorylation.15 Primary
CoQ10 deficiencies are caused by recessive pathogenic
mutations in ubiquinone biosynthesis genes; to date patho-
genic variants in nine genes are reported - PDSS1,16
PDSS2,17 COQ2,18 COQ4,19 COQ6,20 COQ7,21 COQ8A
(ADCK3),22 COQ8B (ADCK4),23 and COQ9.24 As with other
classes of mitochondrial disease, age of onset is varied
and there is considerable phenotypic heterogeneity asso-
ciated with CoQ gene defects. Despite that, some genetic
defects do correlate with characteristic symptoms, for
example renal involvement is frequently observed in
patients with biallelic COQ2 variants25 while patients
harboring recessive defects in COQ8A (ADCK3) often
present with cerebellar ataxia.16 We report two
unrelated female patients who presented in childhood.
Subject 1 had subtle clinical signs of cerebellar ataxia
with unsteadiness, frequent falls and a wide-based gait,
but no upper limb dysmetria, tremor or nystagmus. Sub-
ject 2 had more prominent features of cerebellar ataxia
with similar gait abnormalities, but in addition, dys-
diadochokinesis and intention tremor. Both subjects had
pronounced complex II+III deficiencies, consistent with a
clinical diagnosis of primary CoQ deficiency and addition-
ally, subject 2 was found to have dramatically reduced
CoQ10 levels in muscle. Both subjects were subsequently
found to harbor recessive COQ8A defects and their symp-
toms were responsive to therapeutic CoQ10 which precipi-
tated substantial clinical improvement in walking, gait
stability and cognition. For subject 1, the initial therapeu-
tic dosage of CoQ10 was 100 mg/day which precipitated
pronounced clinical improvement—she was able to walk
greater distances without falls. After 4 months of 100 mg/
day CoQ10 therapy, the dosage was increased to 300 mg/
day which demonstrated continuous improvement in gait.
FIGURE 3 Molecular genetic findings for subject 2. A, Sanger sequencing of genomic DNA from subject 2 (S2), father (F), mother (M) and
control (C) show maternal transmission of the c.1029_1030delinsCA dinucleotide variant that is absent in her father and healthy control. B,
Schematic illustrating the maternally transmitted c.1029_1030delinsCA allele, where X indicates a sequence variant (sample abbreviations as
before). C, Agarose electrophoresis of PCR amplified fibroblast-derived cDNA demonstrates an aberrantly spliced product in subject
2 (S2) relative to an age and tissue matched control cDNA sample (C). N: no template control. DNA marker is 100 bp size standard (Promega cat
G2101). Sanger sequencing of the aberrantly spliced amplicon confirms skipping of exon 6 (C, lower panel) and shows only wildtype sequence
(GG) at nucleotides c.1029_1030 (denoted by an asterisk) confirming in trans variation. D, Agarose electrophoresis of genomic DNA amplified by
long-range PCR shows a smaller amplicon of size ~1.3 kb in the Subject (S2) relative to the control amplicon (C) with the anticipated size
(5.7 kb), consistent with a genomic deletion. N: no template control. Promega 1 kb ladder was used as a size standard. E, Sanger sequencing of
the ~1.3 kb amplicon from subject 2 confirmed a ~4.5 kb deletion, c.730+608_c.854-25del, GRCh38: g.226978131_226982653del. F, BLAT search
and IGV visualization of subject 2's deletion (dashed line) involving intron 5, exon 6 and intron 6
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The therapeutic CoQ10 dosage for subject 2 was 1000 mg,
three times daily, which improved energy levels, exercise
tolerance and gait within a few months. Clinical improve-
ments plateaued despite subsequent increases in CoQ10
dosage.
The homozygous c.1015G>A p.Ala339Thr COQ8A vari-
ant observed in subject 1 is reported once in the literature13
in a pediatric patient with ataxia, cognitive delay and
CoQ10 deficiency; the patient harbored compound heterozy-
gous COQ8A variants but neither variant interpretation nor
a detailed description of the subject's clinical presentation
was reported.13 The c.1015G>A p.Ala339Thr variant is
absent on the Genome Aggregation Database (gnomAD, a
repository of genetic variation from genomic sequencing
projects) and the p.Ala339 residue is evolutionarily con-
served to C. elegans, located in a highly conserved functional
domain required for CoQ10 biosynthesis. Additionally, the
c.1015G>A p.Ala339Thr variant is reported as “likely patho-
genic” on ClinVar (SCV000262867); the variant satisfies
criteria PM1, PM2, PP3, and PP4 according to the ACMG
guidelines,26 fulfilling the requirements for a “likely patho-
genic” status. The CADD scoring system was applied to the
c.1015G>A p.Ala339Thr variant, revealing a score of 25.3
and therefore placing the p.Ala339Thr substitution within
the top 0.5% of the most deleterious variants. While subject
1 was found to harbor a previously reported pathogenic
homozygous COQ8A variant, the genetic diagnosis of sub-
ject 2 was considerably more challenging. The heterozygous
c.1029G>C p.Gln343His and c.1030G>A p.Val344Met vari-
ants were established to be in cis and represented a single
c.1029_1030delinsCA p.Gln343_Val344delinsHisMet vari-
ant, highlighting the importance of establishing phase. Ini-
tial investigations revealed that the c.1029G>C and
c.1030G>A variants are very rare on the gnomAD database
(n = 1 and n = 4 heterozygous cases, respectively); visual
inspection of the raw sequencing data pertaining to the
gnomAD hits revealed the c.1029G>C and c.1030G>A vari-
ants were in cis in one individual and the c.1030G>A vari-
ant occurs as an isolated variant in two cases, which
suggests that the c.1029G>C variant occurred as an ances-
tral mutation on an allele already harboring a c.1030G>A
variant. The Gln343 and Val344 residues are both conserved
to S. cerevisiae, highlighting their functional importance,
reinforced by additional in silico evidence. Classification
of the two variants according to the ACMG guidelines26
does not obviously preclude the functional importance
of either amino acid (Figure S1), and it is not possible to
know whether an allele harboring both the p.Gln343His
and p.Val344Met variants is associated with a more severe
phenotype versus either variant in isolation. Although the
c.1029G>C p.Gln343His, c.1030G>A p.Val344Met and
c.1029_1030delinsCA p.Gln343_Val344delinsHisMet vari-
ants are absent on ClinVar, a c.1028A>G p.Gln343Arg
substitution is reported as “likely pathogenic” on ClinVar
(RCV000195825.1).
Although cDNA investigations revealed skipping of
exon 6, the causative defect was not a consequence of
disrupted splice motifs per se, but a large-scale intragenic
deletion, itself representing a novel mechanism of COQ8A
pathology. The large-scale 4.5Kb deletion is predicted to
cause an in-frame deletion of residues Gly244-Gln284 in
the COQ8A protein. 25/42 residues (60.0%) in exon 6 are
conserved to C. elegans and 15/42 residues (35.7%) are con-
served to S. cerevisiae, supporting the functional impor-
tance of this locus. The g.226978131_226982653del is
unreported on gnomAD,27 ClinVar,28 or the Database of
Genomic Variants (DGV).29 The c.730+608_854-25del,
c.1015G>A, and c.1029_1030delinsCA COQ8A variants
have been submitted to ClinVar (Accession numbers:
SCV000995085, SCV000995086 and SCV000995087).
The presence of biallelic COQ8A variants confirms the
clinical diagnosis of a primary CoQ10 deficiency for both
individuals. In addition to cerebellar ataxia, subject 1 pres-
ented with a number of additional features including hip
dysplasia, macrocephaly, dentinogenesis imperfecta, hyper-
telorism, and exophthalmos; these dysmorphic features are
not consistent with previous COQ8A-deficient phenotypes.
While they may be associated with defective COQ8A, it is
more probable that they are the consequence of a second
gene defect or genomic copy number variation but addi-
tional investigations have not yet been undertaken. The
identification of a very rare variant occurring in the homo-
zygous state in an extensive pedigree with no obvious con-
sanguinity is unusual although not unprecedented30; we
postulate that the c.1015G>A c.Ala339Thr COQ8A variant
may represent a founder mutation given that carrier test-
ing of her unrelated parents supports recessive inheritance.
Subject 2 presented with characteristic features of recessive
COQ8A defects, namely cerebellar ataxia and mild cogni-
tive impairment, but identifying the causative genetic
defect was challenging. Despite initially identifying two
heterozygous variants, both were in cis and therefore were
not sufficient to confirm a genetic diagnosis. cDNA studies
confirmed aberrant splicing, attributable not to defects
involving splicing enhancer or silencer motifs, but an intra-
genic deletion. To the best of our knowledge, this is the
first case of an intragenic genomic deletion in the COQ8A
gene. As diagnostic testing moves towards genomics as a
first line of investigation, this case highlights the impor-
tance of carrier testing and the requirement for additional
analyses to establish the correct genetic diagnosis. Many
NGS sequencing strategies involve short reads and, using
such an approach, it is likely that the intragenic deletion in
subject 2 would have evaded detection. Biochemical evalu-
ation of CoQ10 and mitochondrial respiratory chain activi-
ties using muscle biopsy precipitated the pursuit of COQ8A
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variants, demonstrating the utility of muscle biopsy despite
its increasing displacement as a frontline test. As with
other subjects with reported primary CoQ10 deficiency,
therapeutic administration of CoQ10 has ameliorated
specific symptoms in both patients. This underlines the
importance of rapid identification of the correct genetic
diagnosis as similar patients are likely to respond well to
CoQ10 therapy.
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